Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes - Takeaways - MDSpire

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • By

  • Abiola Bolarinwa

  • Madhu Nagaraj

  • Saurabh Zanwar

  • Nadine Abdallah

  • P. Leif Bergsagel

  • Moritz Binder

  • Francis Buadi

  • Saurabh Chhabra

  • Joselle Cook

  • David Dingli

  • Angela Dispenzieri

  • Morie A. Gertz

  • Wilson Gonsalves

  • Suzanne Hayman

  • Prashant Kapoor

  • Taxiarchis Kourelis

  • Nelson Leung

  • Yi Lin

  • Eli Muchtar

  • Ricardo Parrondo

  • Vivek Roy

  • Taimur Sher

  • Mustaqeem Siddiqui

  • Rahma Warsame

  • Amie Fonder

  • Miriam Hobbs

  • Yi Lisa Hwa

  • Michelle Rogers

  • Udit Yadav

  • J. Erin Wiedmeier-Nutor

  • Linda B. Baughn

  • S. Vincent Rajkumar

  • Rafael Fonseca

  • Sikander Ailawadhi

  • Shaji Kumar

  • April 4, 2025

  • 0 min

Share

  • 1

    Venetoclax is a BCL-2 inhibitor effective in relapsed/refractory multiple myeloma, particularly in patients with t(11;14) translocation.

  • 2

    Response rates for venetoclax-based combinations can reach up to 80%, with significant median progression-free survival in t(11;14) patients.

  • 3

    The CANOVA study did not meet its primary endpoint for progression-free survival in t(11;14) patients, raising concerns about venetoclax's utility.

  • 4

    Secondary cytogenetic abnormalities' impact on venetoclax efficacy remains unclear, highlighting a gap in current research.

  • 5

    Despite high response rates, venetoclax use is cautioned due to potential inferior overall survival linked to higher infection rates.

Original Source(s)

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • by Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, P. Leif Bergsagel, Moritz Binder, Francis Buadi, Saurabh Chhabra, Joselle Cook, David Dingli, Angela Dispenzieri, Morie A. Gertz, Wilson Gonsalves, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Ricardo Parrondo, Vivek Roy, Taimur Sher, Mustaqeem Siddiqui, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Michelle Rogers, Udit Yadav, J. Erin Wiedmeier-Nutor, Linda B. Baughn, S. Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar

  • April 4, 2025

Related Content

Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya

Not all plasma cells are made equal: well-hidden layers of heterogeneity

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines